Mesenchymal Stem Cells Improve Muscle Function Following Single Stretch Injury: A Preliminary Study

Brickson, Stacey; Meyer, Patrick; Saether, Erin E.; Vanderby, Ray

doi:10.3390/jfmk1040396

Cited by 3 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Accumulating evidence suggests that therapeutic stem cell treatments contribute to the regeneration of myofibers and the satellite cell pool after muscle injuries. 5,8,34 In the present study, the regenerated myofibers were more likely newly formed from local muscle cells rather than injected BMMSCs because the PKH26 dyelabeled BMMSCs in the local injection site decayed 21 days after injection (Figure 12). The exact mechanisms underlying the effect of BMMSCs on tissue healing were probably related to their ability to secrete various paracrine factors, thus improving the microenvironment of the injury site to promote myofiber regeneration.…”

Section: Discussionmentioning

confidence: 61%

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

Chiu

Chang

et al. 2020

Am J Sports Med

View full text Add to dashboard Cite

Background: Skeletal muscle injuries are very common in sports medicine. Conventional therapies have limited clinical efficacy. New treatment methods should be developed to allow athletes to return to play with better function. Purpose: To evaluate the in vitro differentiation potential of bone marrow–derived mesenchymal stem cells and the in vivo histologic and physiologic effects of mesenchymal stem cell therapy on muscle healing after contusion injury. Study Design: Controlled laboratory study. Methods: Bone marrow cells were flushed from both femurs of 5-week-old C57BL/6 mice to establish immortalized mesenchymal stem cell lines. A total of 36 mice aged 8 to 10 weeks were used to develop a muscle contusion model and were divided into 6 groups (6 mice/group) on the basis of the different dosages of IM2 cells to be injected (0, 1.25 × 105, and 2.5 × 105 cells with/without F-127 in 100 μL of phosphate-buffered saline). Histological analysis of muscle regeneration was performed, and the fast-twitch and tetanus strength of the muscle contractions was measured 28 days after muscle contusion injury, after injections of different doses of mesenchymal stem cells with or without the F-127 scaffold beginning 14 days after contusion injury. Results: The mesenchymal stem cell–treated muscles exhibited numerous regenerating myofibers. All the groups treated with mesenchymal stem cells (1.25 × 105 cells, 2.5 × 105 cells, 1.25 × 105 cells plus F-127, and 2.5 × 105 cells plus F-127) exhibited a significantly higher number of regenerating myofibers (mean ± SD: 111.6 ± 14.77, 133.4 ± 21.44, 221.89 ± 32.65, and 241.5 ± 25.95, respectively) as compared with the control group and the control with F-127 (69 ± 18.79 and 63.2 ± 18.98). The physiologic evaluation of fast-twitch and tetanus strength did not reveal differences between the age-matched uninjured group and the groups treated with various doses of mesenchymal stem cells 28 days after contusion. Significant differences were found between the control group and the groups treated with various doses of mesenchymal stem cells after muscle contusion. Conclusion: Mesenchymal stem cell therapy increased the number of regenerating myofibers and improved fast-twitch and tetanus muscle strength in a mouse model of muscle contusion. However, the rapid decay of transplanted mesenchymal stem cells suggests a paracrine effect of this action. Treatment with mesenchymal stem cells at various doses combined with the F-127 scaffold is a potential therapy for a muscle contusion. Clinical Relevance: Mesenchymal stem cell therapy has an effect on sports medicine because of its effects on myofiber regeneration and muscle strength after contusion injury.

show abstract

Section: Discussionmentioning

confidence: 61%

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

Chiu

Chang

et al. 2020

Am J Sports Med

View full text Add to dashboard Cite

show abstract

“…Beyond the importance of the cell type, technical considerations for optimization of cell therapy include timing, mode, and location of delivery. Studies with MSC transplantation have indicated the existence of a relatively wide time window of 7 days for cell delivery to still be beneficial . This may simultaneously dispel doubts about administering cells intraoperatively in case of iatrogenic injury and allow surgeons to carefully consider their treatment options.…”

Section: Advances In Treatment Of Local Muscle Injuriesmentioning

confidence: 99%

“…Studies with MSC transplantation have indicated the existence of a relatively wide time window of 7 days for cell delivery to still be beneficial. 158,159 This may simultaneously dispel doubts about administering cells intraoperatively in case of iatrogenic injury and allow surgeons to carefully consider their treatment options. In the vast majority of pre-clinical and clinical studies, cells have been administered by intramuscular injection.…”

Section: Drawbacks and Limitationsmentioning

confidence: 99%

Cell therapy to improve regeneration of skeletal muscle injuries

Qazi

Duda

Ort

et al. 2019

J cachexia sarcopenia muscle

106

128

View full text Add to dashboard Cite

Diseases that jeopardize the musculoskeletal system and cause chronic impairment are prevalent throughout the Western world. In Germany alone, ~1.8 million patients suffer from these diseases annually, and medical expenses have been reported to reach 34.2bn Euros. Although musculoskeletal disorders are seldom fatal, they compromise quality of life and diminish functional capacity. For example, musculoskeletal disorders incur an annual loss of over 0.8 million workforce years to the German economy. Among these diseases, traumatic skeletal muscle injuries are especially problematic because they can occur owing to a variety of causes and are very challenging to treat. In contrast to chronic muscle diseases such as dystrophy, sarcopenia, or cachexia, traumatic muscle injuries inflict damage to localized muscle groups. Although minor muscle trauma heals without severe consequences, no reliable clinical strategy exists to prevent excessive fibrosis or fatty degeneration, both of which occur after severe traumatic injury and contribute to muscle degeneration and dysfunction. Of the many proposed strategies, cell‐based approaches have shown the most promising results in numerous pre‐clinical studies and have demonstrated success in the handful of clinical trials performed so far. A number of myogenic and non‐myogenic cell types benefit muscle healing, either by directly participating in new tissue formation or by stimulating the endogenous processes of muscle repair. These cell types operate via distinct modes of action, and they demonstrate varying levels of feasibility for muscle regeneration depending, to an extent, on the muscle injury model used. While in some models the injury naturally resolves over time, other models have been developed to recapitulate the peculiarities of real‐life injuries and therefore mimic the structural and functional impairment observed in humans. Existing limitations of cell therapy approaches include issues related to autologous harvesting, expansion and sorting protocols, optimal dosage, and viability after transplantation. Several clinical trials have been performed to treat skeletal muscle injuries using myogenic progenitor cells or multipotent stromal cells, with promising outcomes. Recent improvements in our understanding of cell behaviour and the mechanistic basis for their modes of action have led to a new paradigm in cell therapies where physical, chemical, and signalling cues presented through biomaterials can instruct cells and enhance their regenerative capacity. Altogether, these studies and experiences provide a positive outlook on future opportunities towards innovative cell‐based solutions for treating traumatic muscle injuries—a so far unmet clinical need.

show abstract

Mesenchymal Stem Cell Therapy for Sports Injuries - From Research to Clinical Practice

Looi¹,

Eng²,

Liau³

et al. 2020

JSM

View full text Add to dashboard Cite

Mesenchymal Stem Cells Improve Muscle Function Following Single Stretch Injury: A Preliminary Study

Cited by 3 publications

References 49 publications

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

Application of Bone Marrow–Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury in Mice

Cell therapy to improve regeneration of skeletal muscle injuries

Mesenchymal Stem Cell Therapy for Sports Injuries - From Research to Clinical Practice

Contact Info

Product

Resources

About